BioSpace News Archive

This press release corrects and replaces the press release published on 3/8/2023 at 4:03:00 PM ET, as the Adjusted EBITDA Reconciliation table was not included in all previously posted versions of the press release.

Predictive Oncology today issued the following letter to shareholders.

Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the presentation of data in two posters at the American Association for Cancer Research (AACR) Special Conference: Targeting RAS.

Blue Water Vaccines Inc., announced its financial results for the fiscal year ended December 31, 2022 and provided an update on recent business developments and Company progress.

Wiley today announced results for the third quarter ended January 31, 2023.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company) today announced the publication of data evaluating Annamycin’s performance as an anthracycline designed to avoid the cardiotoxicity typically associated with currently prescribed anthracyclines.

Simulations Plus, Inc. announced that its Lixoft division, a leading provider of population PKPD modeling solutions for pharmacometricians and biostatisticians, has released version 2023R1 of its MonolixSuite™ software.

Crown Bioscience and JSR Life Sciences company, announced the opening of a new site in Singapore to expand the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.

Thermoelectric generators are devices that can convert temperature gradients to electricity.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced topline results from the company’s INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo’s investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI.